Zhongjian Chen

Dr. Zhongjian Chen

Shanghai Skin Disease Hospital, Shanghai 200443, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
Haisheng HeHaisheng He
Haisheng He
Yi Lu, Ph.D.Yi Lu, Ph.D.
Yi Lu, Ph.D.
Jianping QiJianping Qi
Jianping Qi
QZQuangang Zhu
Quangang Zhu
Zhongjian ChenZhongjian Chen
Zhongjian Chen
Wei WuWei Wu
Wei Wu
Liposomes mimic natural cell membranes and have long been investigated as drug carriers due to excellent entrapment capacity, biocompatibility and safety. Despite the success of parenteral liposomes, oral delivery of liposomes is impeded by various barriers such as instability in the gastrointestinal tract, difficulties in crossing biomembranes, and mass production problems. By modulating the compositions of the lipid bilayers and adding polymers or ligands, both the stability and permeability of liposomes can be greatly improved for oral drug delivery. This review provides an overview of the challenges and current approaches toward the oral delivery of liposomes.

20 May 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
QLQiuyue Liu
Qiuyue Liu
JZJiahui Zou
Jiahui Zou
Zhongjian ChenZhongjian Chen
Zhongjian Chen
Wei HeWei He
Wei He
Wei WuWei Wu
Wei Wu
Owing to the inherent shortcomings of traditional therapeutic drugs in terms of inadequate therapeutic efficacy and toxicity in clinical treatment, nanomedicine designs have received widespread attention with significantly improved efficacy and reduced non-target side effects. Nanomedicines hold tremendous theranostic potential for treating, monitoring, diagnosing, and controlling various diseases and are attracting an unfathomable amount of input of research resources. Against the backdrop of an exponentially growing number of publications, it is imperative to help the audience get a panorama image of the research activities in the field of nanomedicines. Herein, this review elaborates on the development trends of nanomedicines, emerging nanocarriers, in vivo fate and safety of nanomedicines, and their extensive applications. Moreover, the potential challenges and the obstacles hindering the clinical translation of nanomedicines are also discussed. The elaboration on various aspects of the research trends of nanomedicines may help enlighten the readers and set the route for future endeavors.

1 May 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
WHWeizi Huang
Weizi Huang
Xiying WuXiying Wu
Xiying Wu
JQJianping Qi
Jianping Qi
QZQuangang Zhu
Quangang Zhu
Wei WuWei Wu
Wei Wu
Zhongjian ChenZhongjian Chen
Zhongjian Chen

1 January 2024 in Biofilm
Verified
Journal Article
Open access
XWXiying Wu
Xiying Wu
HWHuan Wang
Huan Wang
JXJuan Xiong
Juan Xiong
GYGuo-Xun Yang
Guo-Xun Yang
JHJin-Feng Hu
Jin-Feng Hu
Zhongjian ChenZhongjian Chen
Zhongjian Chen
Staphylococcus aureus can readily form biofilm which enhances the drug-resistance, resulting in life-threatening infections involving different organs. Biofilm formation occurs due to a series of developmental events including bacterial adhesion, aggregation, biofilm maturation, and dispersion, which are controlled by multiple regulatory systems. Rapidly increasing research and development outcomes on natural products targeting S. aureus biofilm formation and/or regulation led to an emergent application of active phytochemicals and combinations. This review aimed at providing an in-depth understanding of biofilm formation and regulation mechanisms for S. aureus, outlining the most important antibiofilm strategies and potential targets of natural products, and summarizing the latest progress in combating S. aureus biofilm with plant-derived natural products. These findings provided further evidence for novel antibiofilm drugs research and clinical therapies.

30 November 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WZWanting Zhang
Wanting Zhang
YJYuxin Jiang
Yuxin Jiang
YHYonglong He
Yonglong He
HBHamza Boucetta
Hamza Boucetta
JWJun Wu
Jun Wu
Wei HeWei He
Wei He
Messenger RNA (mRNA) is the template for protein biosynthesis and is emerging as an essential active molecule to combat various diseases, including viral infection and cancer. Especially, mRNA-based vaccines, as a new type of vaccine, have played a leading role in fighting against the current global pandemic of COVID-19. However, the inherent drawbacks, including large size, negative charge, and instability, hinder its use as a therapeutic agent. Lipid carriers are distinguishable and promising vehicles for mRNA delivery, owning the capacity to encapsulate and deliver negatively charged drugs to the targeted tissues and release cargoes at the desired time. Here, we first summarized the structure and properties of different lipid carriers, such as liposomes, liposome-like nanoparticles, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles, nanoemulsions, exosomes and lipoprotein particles, and their applications in delivering mRNA. Then, the development of lipid-based formulations as vaccine delivery systems was discussed and highlighted. Recent advancements in the mRNA vaccine of COVID-19 were emphasized. Finally, we described our future vision and perspectives in this field.

1 November 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
ZTZongguang Tai
Zongguang Tai
YHYanping Huang
Yanping Huang
QZQuangang Zhu
Quangang Zhu
Wei WuWei Wu
Wei Wu
TYTao Yi
Tao Yi
Yi Lu, Ph.D.Yi Lu, Ph.D.
Yi Lu, Ph.D.